Oregon Drug Use Review / Pharmacy & Therapeutics Committee  
Thursday, March 21, 2019 1:00 - 5:00 PM  
HP Conference Room  
4070 27th Ct. SE  
Salem, OR 97302  
MEETING AGENDA

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9).

I. CALL TO ORDER

1:00 PM  
A. Roll Call & Introductions R. Citron (OSU)  
B. Conflict of Interest Declaration R. Citron (OSU)  
C. Approval of Agenda and Minutes R. Citron (OSU)  
D. Department Update T. Douglass (OHA)  
E. Legislative Update J. Taylor (OHA)

1:20 PM  
II. CONSENT AGENDA TOPICS T. Klein (Chair)

A. GLP-1 Receptor Agonists Literature Scan  
1. Public Comment

III. DUR ACTIVITIES

1:20 PM  
A. Quarterly Utilization Reports R. Citron (OSU)  
B. ProDUR Report R. Holsapple (DXC)  
C. RetroDUR Report D. Engen (OSU)  
D. Oregon State Drug Reviews K. Sentena (OSU)  
1. Updates on Testosterone Therapy  
2. Basal Insulin Update

IV. DUR OLD BUSINESS

1:45 PM  
A. Calcium/Vitamin D Prior Authorization Update K. Sentena (OSU)  
1. Prior Authorization Update  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA
1:50 PM  B. Hydroxyprogesterone Prior Authorization Update
          1. Prior Authorization Update
          2. Public Comment
          3. Discussion of Clinical Recommendations to OHA

1:55 PM  C. Benzodiazepine Prior Authorization Update
          1. Prior Authorization Update
          2. Public Comment
          3. Discussion of Clinical Recommendations to OHA

2:00 PM  D. Cannabidiol Prior Authorization Update
          1. Prior Authorization Update
          2. Public Comment
          3. Discussion of Clinical Recommendations to OHA

V. PREFERRED DRUG LIST NEW BUSINESS

2:05 PM  A. Tetracycline Class Update and New Drug Evaluation
          1. Class Update
          2. Nuzyra™ (omadacycline) New Drug Evaluation
          4. Public Comment
          5. Discussion of Clinical Recommendations to OHA

2:25 PM  B. Hereditary Angioedema Agents Class Review
          1. Class Review/Prior Authorization
          2. Public Comment
          3. Discussion of Clinical Recommendations to OHA

2:45 PM  C. Endometriosis Class Review
          1. Class Review/Prior Authorization
          2. Public Comment
          3. Discussion of Clinical Recommendations to OHA

3:05 PM  BREAK

VI. DUR NEW BUSINESS

3:15 PM  A. Mental Health Clinical Advisory Group
          1. MHCAG Overview
          2. MHCAG Schizophrenia Algorithm
          3. Public Comment
          4. Discussion of Clinical Recommendations to OHA
3:40 PM  B. Antipsychotics for Schizophrenia Drug Use Evaluation
        1. Drug Use Evaluation and Literature Scan
        2. Provider Education Opportunities
        3. Public Comment
        4. Discussion of Clinical Recommendations to OHA

4:00 PM  VII. EXECUTIVE SESSION

4:50 PM  VIII. RECONVENE for PUBLIC RECOMMENDATIONS

IX. ADJOURN